Intellia Therapeutics (38I) Price & Analysis
38I Stock Chart & Stats
- Day’s Range
- EUR 11.12 - EUR 11.46
- 52-Week Range
- EUR 6.75 - EUR 16.00
- Previous Close
- EUR 11.98
- Volume
- 1,250
- Average Volume (3M)
- 910
- Market Cap
- EUR 1.56B
- Enterprise Value
- EUR 1.89B
- Total Cash (Recent Filing)
- EUR 437.76M
- Total Debt (Recent Filing)
- EUR 73.41M
- Price to Earnings (P/E)
- ―
- Beta
- 1.38
- Next Earnings
- Nov 05, 2026
- EPS Estimate
- -0.71
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Phase III Efficacy
The strong HAELO results provide clinical validation for lonvo-z and support a potentially differentiated one-time treatment profile. Durable efficacy, broad endpoint success, and meaningful quality-of-life improvement can strengthen regulatory and commercial positioning if maintained through approval.
Regulatory Momentum
BLA acceptance and Priority Review materially advance Intellia toward its first potential product launch. A streamlined review path reduces a key development hurdle and could allow the company to establish a leading position in in vivo CRISPR therapy if FDA review is successful.
Funding Runway
A cash runway extending at least into 2028 gives Intellia time to complete regulatory work, prepare commercialization, and advance nex-z without immediate reliance on product revenue. This financial flexibility supports execution through several important clinical and regulatory milestones.
Bears Say
Persistent Cash Burn
Persistent and worsening cash burn reflects the substantial cost of advancing a clinical-stage biotechnology pipeline before commercial revenue is established. Continued losses can consume reserves, increase financing dependence, and limit flexibility if development or launch timelines extend.
Nex-z Safety Risk
The nex-z liver enzyme signal creates a material development and regulatory risk for a major pipeline program. Although Intellia has added monitoring and mitigation, further events could complicate patient selection, delay trials, restrict use, or weaken the program’s commercial opportunity.
Secured Debt Obligations
The loan improves near-term funding capacity but adds secured obligations to a company that continues to generate significant losses. Covenants, collateral requirements, and milestone-based access to remaining proceeds could constrain capital allocation if clinical, regulatory, or commercial progress disappoints.
Intellia Therapeutics News
38I FAQ
What was Intellia Therapeutics’s price range in the past 12 months?
What is Intellia Therapeutics’s market cap?
When is Intellia Therapeutics’s upcoming earnings report date?
How were Intellia Therapeutics’s earnings last quarter?
Is Intellia Therapeutics overvalued?
Does Intellia Therapeutics pay dividends?
What is Intellia Therapeutics’s EPS estimate?
How many shares outstanding does Intellia Therapeutics have?
What happened to Intellia Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Intellia Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Intellia Therapeutics Stock Smart Score
Company Description
Intellia Therapeutics
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- John Leonard
- Employees
- 377
- Website
- www.intelliatx.com
- Address
- 40 Erie Street, Cambridge, MA, 02139, US
Intellia Therapeutics (38I) Earnings & Revenues
38I Earnings Call
Earnings Call SentimentPositive
The call conveyed strong, concrete clinical progress — most notably the unequivocal Phase III success for lonvo‑z (87% attack reduction, 62% attack‑free and therapy‑free, favorable safety) and compelling nex‑z biological data (≈90% TTR knockdown, rapid and durable) — alongside active regulatory and commercial preparations. Financially, the company strengthened its cash position with a ~$195M financing and maintains a runway into at least 2028, although collaboration revenue declined and G&A rose as commercial build‑out continues. The primary concern is a nex‑z liver enzyme safety signal and the identification of an HLA C*05:01 subgroup (~12% of samples) associated with higher Grade 3+ transaminase events; the company has implemented mitigation, added HLA typing to protocols, and is engaging regulators. Overall, the positive clinical milestones and clear mitigation plan for the safety finding outweigh the operational and financial headwinds discussed.
View all DE:38I earnings summaries38I Net sales Breakdown
- 100.00% Collaboration revenue
38I Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 12 | 4 | 6 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 9 | 0 | 3 |